Rapamycin analogs, everolimus and temsirolimus, are approved for the treatment of progress renal cell carcinoma (RCC). was even more effective than temsirolimus in decreasing the development and viability of RCC cell lines, 786-O and Caki-1, by causing cell routine autophagy and police arrest, but not really apoptosis. However, in a xenograft model there was no… Continue reading Rapamycin analogs, everolimus and temsirolimus, are approved for the treatment of